# A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence

> clinical trial · VERIFIED · 2026-08-05

Status: RECRUITING · Sponsor: Tianjin Medical University Cancer Institute and Hospital · Condition: HCC - Hepatocellular Carcinoma

- Company: Tianjin Medical University Cancer Institute and Hospital
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07475026

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.